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S-nitrosylation of proteins by nitric oxide is a major mode of signalling in cells 1 . S-nitrosylation can mediate the regulation of a range of proteins, including prominent nuclear proteins, such as HDAC2 (ref. 2) and PARP1 (ref. 3) . The high reactivity of the nitric oxide group with protein thiols, but the selective nature of nitrosylation within the cell, implies the existence of targeting mechanisms. Specificity of nitric oxide signalling is often achieved by the binding of nitric oxide synthase (NOS) to target proteins, either directly 4 or through scaffolding proteins such as PSD-95 (ref. 5 ) and CAPON 6 . As the three principal isoforms of NOS-neuronal NOS (nNOS), endothelial NOS (eNOS) and inducible NOS (iNOS) -are primarily non-nuclear, the mechanisms by which nuclear proteins are selectively nitrosylated have been elusive. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is physiologically nitrosylated at its Cys 150 residue. Nitrosylated GAPDH (SNO-GAPDH) binds to Siah1, which possesses a nuclear localization signal, and is transported to the nucleus 7 . Here, we show that SNO-GAPDH physiologically transnitrosylates nuclear proteins, including the deacetylating enzyme sirtuin-1 (SIRT1), histone deacetylase-2 (HDAC2) and DNA-activated protein kinase (DNA-PK). Our findings reveal a novel mechanism for targeted nitrosylation of nuclear proteins and suggest that protein-protein transfer of nitric oxide groups may be a general mechanism in cellular signal transduction.
Nuclear GAPDH regulates protein acetylation by binding to, and activating, the acetyltransferases, p300 and CBP 8 . We investigated whether GAPDH might also regulate the reverse process of protein deacetylation by interaction with deacetylases. A two-hybrid-based protein-interaction map of the Drosophila melanogaster proteome 9 revealed a potential physical interaction between GAPDH and the Drosophila protein, Sir2, a prominent NAD-activated nuclear protein deacetylase. This led us to examine whether GAPDH physically interacts with SIRT1, a close mammalian homologue of Drosophila Sir2 (ref. 10) . In intact cells, SIRT1 robustly binds to GAPDH, but only on treatment with the nitric oxide donor, S-nitrosoglutathione (GSNO; Fig. 1a ). These findings do not merely reflect GSNO eliciting movement of GAPDH to the nucleus, as nitrosylation of purified GAPDH is required for its interaction with SIRT1 in vitro (Fig. 1b) . Mutation of the nitrosylated Cys 150 residue of GAPDH abrogates binding ( Supplementary Information, Fig. S1a ). Furthermore, the Cys 150 residue of GAPDH seems to be within the binding site for SIRT1, as a peptide consisting of the ten amino acids that span the Cys 150 region (Peptide-C150), but not a scrambled peptide, selectively prevents the binding of SNO-GAPDH to SIRT1 in vitro (Fig. 1c ). Further characterization of the interaction domain reveals a critical role for Thr 152 of GAPDH, as mutation of this residue abrogates the physical interaction with SIRT1 ( Fig. 1d) .
Given the role of nitric oxide in the GAPDH-SIRT1 interaction, we hypothesized that SIRT1 might also be nitrosylated. To test this, we utilized the biotin switch assay 11 . SIRT1 is nitrosylated in cells treated with GSNO ( Supplementary Information, Fig. S1b ), as well as when exposed to GSNO in vitro ( Supplementary Information, Fig. S1c ), confirming observations from previous studies 12, 13 . To examine whether endogenous SIRT1 is nitrosylated by an endogenous source of nitric oxide, we performed a biotin switch on supernatants from HEK293 cells stably expressing nNOS (HEK293-nNOS; Fig. 2a ). SIRT1 is robustly nitrosylated within 2 h of treatment with the calcium ionophore, A23187, which activates nNOS. SIRT1 is also nitrosylated in mouse embryonic cortical neurons following treatment with the glutamate derivative, N-methyl-d-aspartate (NMDA), which activates nNOS ( Fig. 2b ). Pretreatment of these cells with the specific nNOS inhibitor, Vinyl-l-NIO (L-VNIO), abrogates NMDA-induced SIRT1 nitrosylation.
Mutational analysis identified Cys 387 and Cys 390, residues that are critical to SIRT1 function 14 , as the sites of SIRT1 nitrosylation ( Supplementary Information, Fig. S1d ). As single mutation of either of these residues abolishes the biotin switch signal, it is unclear whether both residues are nitrosylated or allosteric interactions result in the mutation of one residue preventing the nitrosylation of the other. As these two cysteines participate in coordination of a zinc ion, we hypothesized that the mutation of these residues inhibits nitrosylation by eliciting protein misfolding. However, mutation of Cys 363 and Cys 366, which participate with Cys 387 and Cys 390 in zinc ion coordination, has no effect on SIRT1 nitrosylation.
As SNO-GAPDH translocates to the nucleus and binds SIRT1 near its nitrosylated Cys 150 residue, we hypothesized that SNO-GAPDH is the physiological source of nitric oxide for SIRT1 nitrosylation through a protein-protein transnitrosylation reaction. To determine whether SNO-GAPDH can transfer its nitric oxide group to SIRT1, we performed an in vitro transnitrosylation assay ( Fig. 2c and Supplementary Information, Fig. S2a ). Purified GAPDH (wild-type, T152A or C150S) was exposed to GSNO to induce nitrosylation, with glutathione (GSH) treatment as a control. After desalting to remove excess nitric oxide donor, the proteins were incubated with purified SIRT1, followed by a biotin switch assay to determine the extent of SIRT1 nitrosylation. Incubation with wild-type GAPDH, but not GAPDH C150S , leads to nitrosylation of SIRT1, reflecting transfer of the nitric oxide group from the Cys 150 residue of SNO-GAPDH to SIRT1. Furthermore, a binding interaction between the two proteins is required, as mutation of GAPDH Thr 152 abrogates transnitrosylation of SIRT1. Peptide-C150, which blocks the GAPDH-SIRT1 interaction, also prevents SIRT1 nitrosylation by SNO-GAPDH ( Supplementary Information, Fig. S3a ). Additionally, as further evidence for the specificity of the reaction, nitrosylated albumin does not nitrosylate SIRT1 in vitro ( Supplementary Information, Fig. S3b ).
Interestingly, SNO-GAPDH appears to be much more efficient than GSNO at nitrosylating SIRT1, as approximately 0.75 μM total GAPDH leads to substantial SIRT1 nitrosylation in vitro, with the concentration of SNO-GAPDH being less than that of total GAPDH. By contrast, in vitro nitrosylation with GSNO requires a minimum concentration of 10 μM ( Supplementary Information, Fig. S1c ).
To directly examine an influence of GAPDH on SIRT1 nitrosylation in cells, we overexpressed SIRT1 in HEK293-nNOS cells with or without co-overexpression of GAPDH ( Fig. 2d and Supplementary Information, Fig. S2b ). Overexpression of GAPDH leads to substantially elevated levels of SIRT1 nitrosylation. In contrast, β-tubulin is nitrosylated to the same extent in the absence or presence of overexpressed GAPDH. Binding of SIRT1 to GAPDH is required for this effect, as overexpression of GAPDH T152A fails to augment SIRT1 nitrosylation to the same extent as wild-type ( Fig. 2e and Supplementary Information, Fig. S2c ). Mutation of Cys 150 also abrogates the effect of GAPDH on nitrosylation of SIRT1. Importantly, GAPDHmediated nitrosylation of SIRT1 does not require NOS, as overexpression of GAPDH substantially augments SIRT1 nitrosylation in HEK293 cells treated with GSNO ( Supplementary Information, Fig. S3c ). Furthermore, mutation of GAPDH Thr 152 has no appreciable effect on its glycolytic activity ( Supplementary Information, Fig. S3d ). The biotin switch signal from the nitrosylation-null SIRT1 C387S/C390S mutant is unaffected by GAPDH overexpression ( Supplementary Information, Fig. S3e ).
To ascertain whether basal levels of GAPDH physiologically regulate nitrosylation of endogenous SIRT1, we depleted GAPDH from HEK293-nNOS cells by RNA interference, which led to a loss of SIRT1 (a) Endogenous co-immunoprecipitation of SIRT1 and GAPDH in HEK293 cells treated with nitric oxide donor. Cells were treated with GSH or GSNO before lysis. Lysates were immunoprecipitated with immunoglobulin G (IgG) or antibodies specific to SIRT1. SIRT1 and GAPDH were resolved from the immunoprecipitate by SDS-PAGE and identified by western blotting. GAPDH levels in the input are also shown (bottom). (b) Nitrosylated GAPDH (SNO-GAPDH) binds directly to SIRT1 in vitro. GST and GST-GAPDH were pre-treated with GSH or GSNO. Recombinant SIRT1 was added, and binding was assessed by GST pulldown with GSH-agarose beads and identification of proteins by western blotting. (c) A small peptide corresponding to the region of GAPDH that spans Cys 150 (Peptide-C150) blocks the interaction between SNO-GAPDH and SIRT1. GST-GAPDH was treated with GSH or GSNO, before addition of recombinant SIRT1. Peptide-C150 and a scrambled peptide were also added, as indicated. GAPDH binding of SIRT1 was detected by GST pulldown and western blotting. Bottom: sequences of the two peptides used in the assay. The residue corresponding to Cys 150 of GAPDH is indicated in the Peptide-C150 sequence. (d) Mutation of GAPDH Thr 152 abolishes binding to SIRT1. After transfection with wildtype HA-tagged GAPDH or the indicated point mutants, HEK293 cells were treated with GSH or GSNO. Cell lysates were immunoprecipitated with anti-SIRT1 antibody and analysed by western blotting with anti-HA or anti-SIRT1 antibodies. Uncropped images of blots are shown in Supplementary Information, Fig. S5 . nitrosylation, with no alteration in β-tubulin nitrosylation ( Fig. 2f and Supplementary Information, Fig. S2d ). The effect of GAPDH knockdown is rescued by overexpression of wild-type GAPDH, but not GAPDH T152A ( Fig. 2g and Supplementary Information, Fig. S2e ). GAPDH depletion also abolishes nitrosylation of exogenously expressed SIRT1 ( Supplementary Information, Fig. S3f ). Nuclear SNO-GAPDH mediates nitrosylation of SIRT1 through transnitrosylation. (a) HEK293-nNOS cells were treated with A23187 for 2 h, lysed, and the supernatants were then incubated with ascorbate (which initiates the biotin switch), as indicated. Biotinylated SIRT1 was detected by pulldown with neutravidin-agarose and western blotting with anti-SIRT1 antibodies. Bottom: presence of SIRT1 in the input supernatant was detected by western blotting. (b) Mouse cortical neurons were treated with L-VNIO and NMDA, lysed, and the supernatants were treated with ascorbate, as indicated. Biotinylated SIRT1 was detected as in a. Bottom: presence of SIRT1 in the input supernatant was detected by western blotting. (c) In vitro transnitrosylation assay. Recombinant SIRT1 was incubated with or without recombinant GAPDH (wild type, or T152A or C150S mutants) that had been pre-treated with GSH, GSNO or GNSO desalted to remove excess small molecules. A biotin switch assay was then performed, followed by pulldown of biotinylated proteins and western blotting to identify the indicated proteins. (d) HEK293-nNOS cells overexpressing Flag-HA -SIRT1 and co-overexpressing GAPDH, were lysed, and supernatants were treated with ascorbate, as indicated. Proteins, after pulldown from the biotin switch assay, and in the input supernatant, were detected by western blotting. (e) Experiments performed as in d, except HEK293-nNOS cells overexpressing Flag-HA -SIRT1 were co-overexpressing wild-type GAPDH or GAPDH mutants. (f) HEK293-nNOS cells were treated with the indicated shRNA and biotinylation of SIRT1 and β-tubulin was assessed by biotin switch assay and western blotting. (g) HEK293-nNOS cells, or HEK293-nNOS cells overexpressing GAPDH or GAPDH T152A were treated with GAPDH shRNA, as indicated. Biotinylation was assessed by biotin switch assay and western blotting. (h) HEK293T cells were transfected with plasmids encoding HA or HA-Siah1 ΔNLS and treated with or without GSNO, followed by nuclear fractionation. The indicated proteins were detected by western blotting. (i) HEK293-nNOS cells were transfected with plasmid encoding Siah1 ΔNLS or empty control vector. All cells were treated with A23187, and assayed by biotin switch, followed by western blotting. Results from the western blots in this figure are quantified in Supplementary Information, Fig. S2 . Uncropped images of blots are shown in Supplementary Information, Fig. S5 .
These experiments establish that GAPDH-SIRT1 binding is required for SIRT1 nitrosylation, but do not prove that nuclear GAPDH specifically mediates the nitrosylation. Accordingly, we devised an approach to prevent nuclear translocation of GAPDH. GAPDH is translocated to the nucleus by binding to Siah1, which possesses a nuclear localization signal. We employed Siah1 lacking a nuclear localization signal (Siah1 ΔNLS ), which functions in a dominant-negative manner to prevent nuclear translocation of GAPDH ( Fig. 2h ). Siah1 ΔNLS abolishes nitrosylation of endogenous SIRT1, but has no effect on β-tubulin nitrosylation ( Fig. 2i and Supplementary Information, Fig. S2f ). Siah1 ΔNLS also abolishes nitrosylation of exogenously expressed SIRT1 ( Supplementary  Information, Fig. S3g ).
If SNO-GAPDH physiologically nitrosylates SIRT1, it should also regulate the effect that nitrosylation has on the catalytic activity of SIRT1. To test this, we utilized an in vitro histone deacetylation assay. GSNO treatment inhibits SIRT1 catalytic activity ( Fig. 3a) , confirming observations from previous studies 12, 13 that nitrosylation inhibits the enzymatic function of SIRT1. SNO-GAPDH also inhibits SIRT1 activity, an effect that is abolished by mutation of Thr 152 (Fig. 3b ) or Cys 150 ( Supplementary Information, Fig. S3h ) of GAPDH.
We examined regulation of SIRT1 by SNO-GAPDH in intact cells. GAPDH augments the acetylation of numerous substrates by p300-CBP 8 . PGC1α, which is deacetylated exclusively by SIRT1 (ref. 15) , is one of the few, if not the only, SIRT1 substrates that is not acetylated by p300-CBP 16 , and so is an optimal substrate for experiments investigating the functional effects of GAPDH transnitrosylation of SIRT1. Treatment of HEK293-nNOS cells with A23187 leads to substantially elevated levels of acetylated PGC1α, reflecting inhibition of SIRT1 enzyme activity (Fig. 3c ). The effect of A23187 reflects Ca 2+ -calmodulin (CaM)activation of nNOS, as A23187 has no effect on PGC1α acetylation in HEK293 cells. Depletion of GAPDH in HEK293-nNOS cells by RNA interference reduces levels of acetylated PGC1α, consistent with preventing the SNO-GAPDH mediated transnitrosylation and inhibition of SIRT1 ( Fig. 3d ). Conversely, overexpression of GAPDH in HEK293-nNOS cells markedly increases PGC1α acetylation ( Supplementary  Information, Fig. S3i ). Nuclear localization of GAPDH is required for this effect, as GAPDH K225A , which does not enter the nucleus 7 , fails to inhibit PGC1α deacetylation. PGC1α is a transcriptional co-activator that induces gluconeogenic gene expression through its interaction with the transcription factor HNF4α 17 . Acetylation of PGC1α prevents its co-activation of HNF4α 15 . To further explore the physiological effects of GAPDH-mediated nitrosylation of SIRT1, we utilized a luciferase reporter assay to measure PGC1α-HNF4α transcriptional activity. As predicted, depletion of GAPDH leads to a substantial increase in PGC1α-HNF4α transcriptional activity, an effect that is rescued by overexpression of wild-type GAPDH, but not GAPDH T152A (Fig. 3e) .
These experiments establish that nitrosylation of nuclear SIRT1, and inhibition of its catalytic activity, are physiologically mediated by nuclear SNO-GAPDH through transnitrosylation. Next, we investigated whether this process is limited to SIRT1 or reflects a more general mechanism for nitrosylating nuclear proteins. We first examined HDAC2, a nuclear protein shown to be physiologically nitrosylated 2 . GAPDH binds to HDAC2 in intact cells treated with GSNO ( Fig. 4a ). We confirmed nitrosylation of endogenous HDAC2 and demonstrated that depletion of GAPDH by RNA interference abolishes this nitrosylation (Fig. 4b ). HDAC2 nitrosylation requires nuclear localization of GAPDH, as the nitrosylation is inhibited in cells expressing Siah1 ΔNLS (Fig. 4c ). DNA-PK was also recently shown to be nitrosylated 18 , and we identified it in a screen for nuclear proteins that have enhanced nitrosylation when GAPDH is overexpressed ( Supplementary  Information, Fig. S4 ). As with SIRT1 and HDAC2, nitrosylation of endogenous DNA-PK is abolished by depletion of GAPDH by RNA interference (Fig. 4d ), as well as by expression of the Siah1 ΔNLS dominant-negative construct (Fig. 4e) .
The present study has established that nuclear proteins such as SIRT1, HDAC2 and DNA-PK are physiologically transnitrosylated by SNO-GAPDH. The transnitrosylative transfer of nitric oxide from haemoglobin to the anion exchanger AE1 at the plasma membrane of red blood cells has been previously reported, implicating the process in the systemic transport and release of nitric oxide bioactivity 19 . Not only was haemoglobin required for AE1 nitrosylation, but transfer of nitric oxide from haemoglobin to AE1 was necessary for nitric-oxide-induced hypoxic vasodilation. Subsequently, the movement of nitric oxide from Cys 73 of thioredoxin-1 to caspase-3 20, 21 , and the denitrosylation of caspase-3 by thioredoxin-1 and -2 through a conserved Cys 32 residue 22 , have been reported. Very recently, it has been noted that caspase-3 can transfer nitric oxide to the anti-apoptotic protein XIAP 23 . Our findings firmly establish a role for protein-protein transnitrosylation in intracellular signalling by nitric oxide. Specifically, our identification of GAPDH-mediated nitrosylation of proteins following nuclear translocation reveals a mechanism for the selective propagation of nitrosylationdependent signals between subcellular loci, yielding new insight into the compartmentalization of nitric oxide bioactivity. There are some reports in the literature of nuclear localization of NOS. Nuclear eNOS and iNOS have been described in rodent brown adipocytes 24 , and nuclear translocation of eNOS has been observed in estradiol-treated endothelial cells 25, 26 . The physiologic relevance of these reports is unclear, as most studies have found eNOS excluded from the nucleus, cycling instead between soluble and membrane-bound cytosolic compartments 27 . Major reductions have been found in eNOS catalytic activity when it is targeted to the nucleus through fusion to an exogenous nuclear localization signal 28 . To our knowledge, there are no reports of nuclear nNOS. In the present study, we have found that GAPDH mediates SIRT1 nitrosylation independently of NOS, as overexpression of GAPDH augments SIRT1 nitrosylation following treatment with nitric oxide donor in cells lacking NOS expression ( Supplementary  Information, Fig. S3c ).
We have shown that transnitrosylation by GAPDH inhibits SIRT1 enzymatic activity, leading to decreased transcriptional activity of PGC1α, a well established SIRT1 substrate. Given the importance of SIRT1 regulation of PGC1α in metabolic pathways 29 , and particularly in the metabolic dysfunction associated with obesity 30, 31 , the effect of GAPDH on the SIRT1-PGC1α pathway may have clinical relevance. Chronic inflammation is associated with the metabolic alterations seen in type 2 diabetes 32 , and nitric oxide is a major mediator of inflammation 33 . Thus, GAPDH-mediated inhibition of SIRT1 may afford a link between inflammation and metabolic dysfunction.
Because of its abundance in all cells and its well characterized nuclear translocation following nitrosylation, GAPDH is ideally suited to donate nitric oxide to nuclear proteins. In addition to proteins that primarily exist in the nucleus, transcription factors function in the nucleus, but often cycle between the nucleus and cytosol, and some have been shown to be physiologically nitrosylated (for example, NFkB 34 and HIF1α 35 ). It seems reasonable to speculate that some of these proteins may also be targets of transnitrosylation by SNO-GAPDH. Thus, SNO-GAPDH may regulate diverse nuclear activities. We have also detected substantial levels of SNO-GAPDH in cytosolic extracts (data not shown), suggesting that GAPDH may transnitrosylate cytosolic targets. Besides its conventional catalytic activity, GAPDH has been implicated in other cellular events such as transcriptional regulation 36 , DNA repair 37 , nuclear export of tRNAs 38 and regulation of mRNA stability 39 .
In summary, our findings establish a novel signalling pathway whereby nuclear proteins can be physiologically nitrosylated, with GAPDH providing nuclear access for nitric oxide. Binding of GAPDH to target proteins provides selectivity in the nitrosylation process. Earlier formulations of nitric oxide as freely diffusing within cells failed to explain specificity of signalling. The binding of NOS isoforms directly to targets 4 , or through scaffolding proteins such as CAPON 6 , facilitates the selectivity for cytosolic proteins. Transnitrosylation through GAPDH extends such specificity to nuclear proteins with substantial functional implications. Protein-protein transnitrosylation may be a general mechanism for selectively propagating the nitric oxide signal within defined cellular pathways.
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AutHoR coNtRibutioNS
Cell culture. HEK293 and HEK293T cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) plus 10% (v/v) fetal bovine serum (FBS), 1 mM l-glutamine, and Penicillin-Streptomycin, at 37 °C with a 5% CO 2 atmosphere in a humidified incubator. HEK293-nNOS cells were maintained as above but with Penicillin-Streptomycin-Neomycin. All transfections were performed with PolyFect reagent (Qiagen) according to the manufacturer's instructions. Mouse embryonic cortical neurons were maintained in Neurobasal medium including B27 supplement, and experiments were performed at 7 days in vitro (DIV 7). To activate NMDA receptors, neurons were treated with Mg 2+ -free Earle's balanced salt solution containing 300 μM NMDA and 5 μM glycine for 10 min. The NMDA-containing solution was then removed, fresh Neurobasal medium with B27 supplement was added, and neurons were incubated at 37 °C for another 16 h, before being subjected to the biotin switch assay.
RNA interference. Two methods for RNA interference were used in this study. In the first, control and GAPDH RNA interference were performed using, respectively, non-silencing-and GAPDH-GIPZ lentiviral microRNA-adapted shRNA (shRNAmir) viral particles from Open Biosystems according to the manufacturer's instructions. After infection, 1 mM sodium pyruvate was added to the culture medium, along with 10 μg ml -1 puromycin (selection marker).
In the second method, used in Figure 2g , small oligonucleotides from Dharmacon RNA Technologies were used as previously described 7 . For rescue experiments, transfection with rescue plasmids occurred 24 h after siRNA treatment. Cells were then incubated at 37 °C for another 24 h before lysis. The rescue plasmids were not RNAi resistant; rather, rescue was achieved (and confirmed through western blot) by the high level of expression of the plasmids.
Western blotting. Western blots were visualized using either the SuperSignal West ECL system from Pierce followed by film exposure or the LI-COR Odyssey infrared imaging system.
Immunoprecipitation. For SIRT1-GAPDH co-immunoprecipitation, cells were lysed in binding buffer (50 mM Tris at pH 7.4, 150 mM NaCl, 0.1% (w/v) Chaps, 100 μM deferoxamine, 1 mM EDTA (ethylenediaminetetraacetic acid) and 0.1 mg ml -1 bovine serum albumin; BSA) and homogenized by passing through a 26-gauge needle. Cell extracts were subjected to immunoprecipitation with anti-SIRT1 or anti-HDAC2 antibody and 30 μl TrueBlot anti-Rabbit IgG immunoprecipitation beads for either 3 h or overnight at 4 °C. The beads were washed five times with binding buffer.
For PGC1α immunoprecipitation, cells were lysed by sonication in lysis buffer (50 mM Tris at pH 8.0, 100 mM NaCl, 2 mM EGTA (ethylene glycol tetraacetic acid), 0.4% (v/v) Triton X-100, 10 mM nicotinamide, 10 μM TSA (trichostatin A) and 100 μM deferoxamine), and extracts were subjected to immunoprecipitation with anti-flag antibody and Protein G agarose beads (Calbiochem) for a minimum of 3 h at 4 °C. Beads were washed four times with lysis buffer. DOI: 10.1038/ncb2114 GAPDH glycolytic activity assay. This assay was performed as previously described 7 .
Statistical analysis. P values were calculated by student's t-test or one-way ANOVA using Microsoft Excel. In vitro transnitrosylation assay performed as in Fig. 2 , with the exception that, after the labeling step, biotinylated proteins were precipitated with NeutrAvidin-agarose before being resolved by SDS-PAGE and probed with specific antibodies. (c) Overexpression of GAPDH augments SIRT1 nitrosylation in 293 cells treated with NO donor. Forty-eight hours after transfection with FH-SIRT1 and either HA-GAPDH or empty HA vector, cells were treated with 500 mM GSH or GSNO for 3 hr and subjected to the biotin switch assay. (d) Mutation of GAPDH-T152 has no appreciable effect on its glycolytic activity. n=4, mean±s.e.m. (e) Overexpression of GAPDH has no effect on the biotin switch signal for FH-SIRT1-C387/390S. The assay was performed from 293-nNOS cells transfected with the indicated plasmids and treated with A23187 (5 mM) for 2 hr. Figure S4 An unbiased screen identifying DNA-PK as a target of SNO-GAPDH-dependent S-nitrosylation. Biotin switch assay from 293-nNOS crude nuclear lysates, with or without GAPDH overexpression. After pulldown, proteins were eluted from NeutrAvidin-agarose with b-mercaptoethanol, resolved by SDS-PAGE, and visualized by silver stain (SilverSNAP Stain Kit II, Pierce). The indicated bands were excised from the gel and sent for analysis by mass spectrometry (Taplin Mass Spectrometry Facility, Harvard University). The biotin switch signal from the upper band, which consisted primarily of DNA-PK, was the most consistently and substantially enhanced by GAPDH overexpression. Therefore, DNA-PK was followed up as a potential target of GAPDHmediated transnitrosylation. Figure S5 
